The promise of gene quantification.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Radich.
Explore the source record for details and available documents.
The study of minimal residual disease is an attempt to redefine the concept of remission. Opinion as to the clinical utility of minimal residual disease is still in evolution. It has become clear that the ability to merely detect minimal residual disease by the polymerase chain reaction amplification of the molecular "fingerprint" of a leukemia does not always foretell relapse. Rather, careful consideration must be taken of the context of the type of disease, the molecular lesion itself, and the type of therapy employed. Thus although the detection of minimal residual disease in acute lymphoblastic leukemia or acute promyelocytic leukemia has a high correlation with relapse, detection of minimal residual disease in t(8;21) acute myelogenous leukemia has little correlation with relapse. In some diseases (eg. chronic myeloid leukemia) the clinical relevance of minimal residual disease detection may be strengthened by quantification, although this in itself introduces another level of complexity and potential pitfalls. Nevertheless, we are moving toward the day when the molecular definition of disease status will guide therapy.
Fluorescence in situ hybridization (FISH) was used to discriminate between benign and malignant cells in sorted populations of chronic myelogenous leukemia (CML) marrow. FISH has the advantage of allowing for a cell by cell analysis of the breakpoint cluster region (BCR) gene rearrangement immediately after flow sorting in nondividing G0/G1 cells that are potentially transcriptionally inactive. We initially selected CD34+ cells with very low expression of the activation antigen CD38 as a candidate phenotype for an immature and hypothetically more benign cell population, but found no enrichment for Ph negativity in that subtype. In five CML samples, 55% +/- 3.3% (mean +/- SE) of CD34+/CD38hi cells had the BCR gene rearrangement, similar to 57% +/- 3.7% seen in the CD34+/CD38lo population. In contrast, subsequent experiments (n = 4) determined that the CD34+/HLA-DRlo population in CML marrow does contain an increased proportion of benign cells: 15% +/- 1% of the CD34+/DRlo cells were BCR rearranged, compared with 52% +/- 5.8% of the CD34+/DRhi cells (P = .001). Our results indicate that benign progenitors in CML are enriched within the CD34+ cells with low DR antigen expression, but not low CD38 expression. One possible interpretation of these observations is that low CD38 antigen expression is not as useful as low HLA-DR expression for isolating immature cells.
The study of minimal residual disease has been fueled by the technologic advent of the polymerase chain reaction and basic developments identifying the genetic lesions involved in human malignancies. Thus far advances in identifying, cloning, and the subsequent polymerase chain reaction amplification of relevant genes have outpaced clinical studies designed to tell us the significance of minimal residual disease. It has become clear that the mere detection of minimal residual disease does not foretell relapse; thus, although the presence of minimal residual disease in acute lymphoblastic leukemia and acute prolymphocytic leukemia appears to be associated with a high risk of relapse, the presence of minimal residual disease in t(8;21) acute myeloid leukemia, chronic myeloid leukemia, and t(14;18) non-Hodgkin's lymphoma is not clearly associated with impending relapse. In most situations there is clearly a need for carefully controlled studies to evaluate the predictive value of minimal residual disease.
We describe a multiplex PCR assay for the detection of bcr-abl fusion mRNA in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL). The assay provides a quick method for screening p190 (e1:a2) and p210 (b2:a2 or b3:a2) bcr-abl mRNAs simultaneously. The assay proves to be highly sensitive with detection of as little as one positive bcr-abl-expressing cell in a background of 10(5) negative bcr-abl cells. Bone marrow and peripheral blood specimens from six patients were in total accordance when run by multiplex PCR and by the single primer PCR approach. The multiplex bcr-abl assay may prove to be highly useful for screening newly diagnosed patients with ALL for the bcr-abl fusion transcript and in following the course of disease during therapy.
Based on our understanding of CML, we recommend that patients age 65 or less with newly diagnosed CML should be evaluated to determine the stage of their disease and should be human lymphocyte antigen-typed along with their siblings. Patients age 55 years and younger who have matched or single antigen mismatched siblings should be advised to undergo BMT as soon as possible and patients up to age 65 should be considered for BMT early in their disease course if in good health. Patients age 55 years or younger without appropriately matched family member donors should have a search for an unrelated donor initiated and should be offered BMT if an appropriate donor is found. Patients for whom no donor is found and older patients without family matches can be considered for entry onto clinical trials evaluating autologous BMT or other experimental approaches.
We studied 20 patients who had received allogeneic bone marrow transplants for acute lymphoblastic leukemia. Using the polymerase chain reaction (PCR), we examined them for the presence of immunoglobulin heavy chain variable-diversity-junctional (IgH V-D-J) gene rearrangements as a marker of minimal residual disease (MRD). Seventeen of the patients were transplanted in relapse or for primary refractory disease, and three were transplanted in "high risk" remission. Thirteen patients had at least one positive PCR assay for MRD in the first 100 days after transplant; two died of nonleukemic causes, while all the remaining 11 relapsed. Seven patients had all negative PCR assays; two died of nonleukemic causes, four remain alive and well, and one patient with consistently negative PCR assays relapsed 47 days after his last negative test. Considering PCR status as a time-dependent covariate, the relative risk of relapse for PCR-positive patients compared to PCR-negative patients is 6.4 (p = 0.0067; 95% CI, 1.6-24.4), and the relative risk of relapse or death is 4.8 (p = 0.0052; 95% CI, 1.6-14.2). The Kaplan-Meier estimate of relapse at 1 year for PCR-positive patients is 100% compared to 33% for PCR-negative patients. The estimate for disease-free survival at 1 year for PCR-positive patients is 0% compared to 44% at 3 years for the PCR-negative group. The PCR assay for MRD appears to be a sensitive and specific test, identifying patients at high risk of relapse following allogeneic BMT who might benefit from further therapeutic interventions.
Explore the source record for details and available documents.
We describe a rapid and efficient RT-PCR method particularly suited to procedures involving limited cell and target gene copy numbers. Purified leukocytes and myeloid colonies derived from patients with chronic myelogenous leukemia (CML) in chronic phase were used for direct RT-PCR. Purified cells and colonies were lysed using a small quantity of DEPC-treated water containing RNasin as an RNA inhibitor. The untreated lysate was either used immediately for RT-PCR or frozen at -70 degrees C for later use. By this method we were able to consistently amplify bcr-abl transcripts from as few as 10 cells. No noticeable difference was observed between products amplified from fresh and frozen samples.
Homeobox genes are members of a family of transcription factors that regulate tissue development in many different organisms. We set out to identify homeobox genes that might play a role in hematopoiesis. Using degenerate oligonucleotide primers corresponding to conserved homeobox sequences in the polymerase chain reaction (PCR), we cloned from the HL60 promyelocytic cell line a homeobox gene we now designate PRH. We mapped this gene, which was not homologous to any of the previously described homeobox genes, to chromosome 10, a region outside of the known genomic homeobox clusters. Northern blot hybridization indicates that PRH is preferentially expressed in myeloid and liver cells. The structure, chromosomal location, and pattern of expression of PRH indicate that it represents an orphan homeobox gene that may regulate the lineage development of certain hematopoietic cells.
Point mutations of the N-ras oncogene are relatively common in acute myelogenous leukemia (AML) cells, occurring in some 25% to 50% of patient samples. We used a technique involving the direct nucleotide sequencing of in vitro amplified N-ras genomic fragments to determine the frequency of N-ras point mutations in chronic myeloid leukemia (CML) cells at various stages of the disease. This approach will detect N-ras point mutations in a mixed population of cells if the mutation is present in 25% or more of the cells. We could not demonstrate any point mutation at N-ras codons 12,13 or 59-63 in any of the 44 CML cases analyzed, which included 21 blast crisis samples. In contrast with AML N-ras point mutations are exceedingly rare in CML.
The phenotype and, by inference, the cell of origin of some lymphocytic neoplasms has been defined by surface marker studies; however, the precise cellular origin of other neoplasms of the lymphoid system is still unknown. For example, with reference to hairy cell leukemia (HCL), cell marker data has been used in support of a monocytic, a T cell, or a B cell origin. If hairy cell leukemia is a B cell-derived neoplasm, the controversy may be resolved by genotyping the cells, using the rearrangement of immunoglobulin genes as a marker of the B cell nature of the process. Rearrangement of these genes is detected using the Southern blot technique and cloned probes specific for the JH segment of the immunoglobulin genes. In this study, the arrangement of the immunoglobulin genes was analysed in normal tissue, in two accepted B cell lymphomas and in nine cases of hairy cell leukemia. DNA from peripheral blood leukocytes (two patients) and from the spleen (seven patients) revealed a discrete new JH restriction fragment length in the leukocytes of hairy cell leukemia cases. The presence of rearranged restriction fragments is interpreted as evidence of the existence of clonal B cell populations. Three of six samples had rearranged kappa light chain fragments. We conclude that most cases of hairy cell leukemia have a B cell genotype. The use of genotyping has wider application in the analysis of hematological malignancies.